WOCKPHARMA: H1 consolidated PBT turned positive as standalone net profit rose to Rs 207 crore
NiveshIQ
NSE: WOCKPHARMA · Healthcare
Wockhardt Ltd.
₹1,896.50▼ ₹4.60 (-0.24%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on WOCKPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Wockhardt Ltd.
Wockhardt Limited is a diversified pharmaceutical and biotech firm operating in India, the United States, and Europe, with a product portfolio that spans generic drugs, specialty antibiotics, and biologics. Its core revenue drivers include the manufacturing of generic formulations and the commercialisation of specialty antibiotics such as ZAYNICH, FOVISCU, MIQNAF, and ODRATE, which target resistant bacterial infections. In 2023, the company reported revenue of ₹3,653 crore and a net income of ₹409 crore, reflecting steady growth in its specialty segment. Recent developments include the launch of new antibiotic candidates and continued investment in insulin analogs and GLP‑1 agonists, positioning Wockhardt to capture emerging therapeutic niches. The firm maintains a competitive edge through
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,798 Cr +5.55% | ₹3,012 Cr +7.65% | ₹3,373 Cr +11.99% |
| EBITDA Margin | 1.39% | 13.05% | 19.33% |
| Net Profit | -24.00% | -87.90% | ₹213.00 Cr -449.10% |
| EPS | ₹-32.05 | ₹-3.02 | ₹13.12 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Wockhardt Q2 FY27 Results: Revenue, Profit and Key Figures
Wockhardt Limited (WOCKPHARMA.NS) Seasonal returns chart
🔒
+ 3 more stories about Wockhardt Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹969 Cr, PAT ₹79 Cr, EPS ₹4.85, EBITDA margin 17.9%. Growth context: revenue YoY +23.9%, PAT YoY +1.3%, revenue QoQ +4.3%, PAT QoQ -25.5%.
Management highlights new capacity additions, capex deployment, order wins, deal pipeline, and backlog build as the prim...
FY26 (last completed FY): revenue ₹3, 373 Cr, PAT ₹213 Cr, EBITDA margin 19.3%, EPS ₹13.12. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Syngene International Ltd.Thyrocare Technologies Ltd.Torrent Pharmaceuticals Ltd.Ventive Hospitality Ltd.Vijaya Diagnostic Centre Ltd.Viyash Scientific Ltd.Yatharth Hospital & Trauma Care Services Ltd.Zydus Lifesciences Ltd.Aarti Drugs Ltd.Aarti Pharmalabs Ltd.Abbott India Ltd.Acutaas Chemicals Ltd.
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for WOCKPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track WOCKPHARMA alongside your other holdings
Unlock full WOCKPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Wockhardt Ltd.?
NiveshIQ detects active intelligence signals for Wockhardt Ltd. (WOCKPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Wockhardt Ltd.?
Wockhardt Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,616,936.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.